Regend Therapeutics

Privately held: no public share price · China

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
Airway epithelial regeneration (autologous basal cells)Cell therapy
Chronic Obstructive Pulmonary Disease
Phase 1
Renal progenitor cell therapyCell therapy
Type 2 DiabetesChronic Kidney Disease
Phase 1
Airway basal layer stem cellsCell therapy
Chronic Obstructive Pulmonary Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
September 2028 (1)
REGEND001Phase 3COPD (Chronic Obstructive Pulmonary Disease)
Est. primary completion 2028-09 · NCT07828353 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.